GlobeNewsWire
25 Aug 2026, 22:35 UTC · 1w ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
4 claims · each scored for market impact
Emergent BioSolutions cut its full-year revenue guidance by approximately 10.8% at the midpoint. — Guidance cuts typically signal deteriorating business fundamentals and lead to valuation downgrades.
-0.70Emergent BioSolutions recorded a $191.3 million non-cash impairment charge on the NARCAN asset group. — A significant impairment charge indicates a permanent decline in the value of a core asset, impacting the balance sheet.
-0.60Management cited increased competitive intensity as the cause for the NARCAN asset impairment and weakened outlook. — Structural competitive pressure suggests a long-term erosion of pricing power and market share.
-0.50Continue reading
6 related stories
Search tags
Pomerantz LLP is investigating Emergent BioSolutions for potential securities fraud or unlawful business practices. — The initiation of a securities fraud investigation increases legal risk and potential future liabilities.
Which stocks this story touches
The company faces a securities fraud investigation, a significant impairment charge, a GAAP net loss, and reduced revenue guidance.
The company is the subject of a legal investigation into claims on behalf of investors.
The company is the subject of a legal investigation into claims on behalf of investors.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
4h ago
